Affitech A/S
Major shareholder transaction: Notification pursuant to Section 28a of the Danish Securities Trading Act
Affitech A/S 06.09.2012 16:32 Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Release no. 27/2012 Copenhagen and Oslo, 2012-09-06 16:32 CEST (GLOBE NEWSWIRE) -- In accordance with Section 28a of the Danish Securities Trading Act, this is to notify, on behalf of Alexander Shuster, Chairman of the Board of Directors of Affitech A/S, of the following transactions: Name Trans Nova Investments Limited -------------------------------------------------------------------------------- Reason for reporting Related party to Alexander Shuster, Chairman of the Board of Affitech A/S -------------------------------------------------------------------------------- Issuer and ISIN Affitech A/S/DK0015966592 -------------------------------------------------------------------------------- Type of transaction Purchase of shares -------------------------------------------------------------------------------- Relevant market NASDAQ OMX COPENHAGEN A/S -------------------------------------------------------------------------------- Date of transaction 5th September, 2012 -------------------------------------------------------------------------------- Number of traded securities 97,573 shares. Market value DKK 19,466 and market value -------------------------------------------------------------------------------- Date of transaction 6th September, 2012 -------------------------------------------------------------------------------- Number of traded securities 62,517 shares. Market value DKK 12,503 and market value -------------------------------------------------------------------------------- About Affitech Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS(TM) (Cell Based Antibody Selection) is Affitech's premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS(TM). Further information is available at www.affitech.com. Contact Randi Krogsgaard, Director IR & Communications Tel # +45 2320 1001, e-mail: ir@affitech.com News Source: NASDAQ OMX 06.09.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Affitech A/S Denmark Phone: Fax: E-mail: Internet: ISIN: DK0015966592 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found